vs

Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $20.2M, roughly 1.4× La Rosa Holdings Corp.). La Rosa Holdings Corp. runs the higher net margin — -27.4% vs -71.0%, a 43.6% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 3.2%).

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

LRHC vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.4× larger
ZYME
$27.6M
$20.2M
LRHC
Growing faster (revenue YoY)
ZYME
ZYME
+69.4% gap
ZYME
72.6%
3.2%
LRHC
Higher net margin
LRHC
LRHC
43.6% more per $
LRHC
-27.4%
-71.0%
ZYME

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
LRHC
LRHC
ZYME
ZYME
Revenue
$20.2M
$27.6M
Net Profit
$-5.5M
$-19.6M
Gross Margin
8.4%
Operating Margin
-24.7%
-80.1%
Net Margin
-27.4%
-71.0%
Revenue YoY
3.2%
72.6%
Net Profit YoY
-125.7%
34.3%
EPS (diluted)
$-5.44
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LRHC
LRHC
ZYME
ZYME
Q3 25
$20.2M
$27.6M
Q2 25
$23.2M
$48.7M
Q1 25
$17.5M
$27.1M
Q4 24
$17.7M
$31.0M
Q3 24
$19.6M
$16.0M
Q2 24
$19.1M
$19.2M
Q1 24
$13.1M
$10.0M
Q3 23
$6.8M
Net Profit
LRHC
LRHC
ZYME
ZYME
Q3 25
$-5.5M
$-19.6M
Q2 25
$78.4M
$2.3M
Q1 25
$-95.7M
$-22.6M
Q4 24
$-5.1M
$-23.5M
Q3 24
$-2.5M
$-29.9M
Q2 24
$-2.3M
$-37.7M
Q1 24
$-4.6M
$-31.7M
Q3 23
$-343.8K
Gross Margin
LRHC
LRHC
ZYME
ZYME
Q3 25
8.4%
Q2 25
8.0%
Q1 25
8.8%
Q4 24
8.9%
Q3 24
8.3%
Q2 24
8.3%
Q1 24
8.9%
Q3 23
8.5%
Operating Margin
LRHC
LRHC
ZYME
ZYME
Q3 25
-24.7%
-80.1%
Q2 25
-10.6%
-1.4%
Q1 25
-26.7%
-94.5%
Q4 24
-17.1%
-71.6%
Q3 24
-8.9%
-213.8%
Q2 24
-9.7%
-222.9%
Q1 24
-35.0%
-376.9%
Q3 23
-6.1%
Net Margin
LRHC
LRHC
ZYME
ZYME
Q3 25
-27.4%
-71.0%
Q2 25
337.8%
4.8%
Q1 25
-546.5%
-83.5%
Q4 24
-28.7%
-75.8%
Q3 24
-12.5%
-186.6%
Q2 24
-12.2%
-195.8%
Q1 24
-35.1%
-315.6%
Q3 23
-5.1%
EPS (diluted)
LRHC
LRHC
ZYME
ZYME
Q3 25
$-5.44
$-0.26
Q2 25
$15.25
$0.03
Q1 25
$-5.86
$-0.30
Q4 24
$28.54
$-0.32
Q3 24
$-16.49
$-0.39
Q2 24
$-12.49
$-0.49
Q1 24
$-0.35
$-0.42
Q3 23
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LRHC
LRHC
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$4.0M
$64.8M
Total DebtLower is stronger
$642.8K
Stockholders' EquityBook value
$1.6M
$320.1M
Total Assets
$21.7M
$397.3M
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LRHC
LRHC
ZYME
ZYME
Q3 25
$4.0M
$64.8M
Q2 25
$5.1M
$98.3M
Q1 25
$2.9M
$76.2M
Q4 24
$1.4M
$66.1M
Q3 24
$1.8M
$122.4M
Q2 24
$1.6M
$71.0M
Q1 24
$1.1M
$114.8M
Q3 23
$350.3K
Total Debt
LRHC
LRHC
ZYME
ZYME
Q3 25
$642.8K
Q2 25
$644.3K
Q1 25
$645.9K
Q4 24
$647.6K
Q3 24
$649.2K
Q2 24
$650.8K
Q1 24
$652.4K
Q3 23
Stockholders' Equity
LRHC
LRHC
ZYME
ZYME
Q3 25
$1.6M
$320.1M
Q2 25
$3.4M
$334.5M
Q1 25
$-87.5M
$325.0M
Q4 24
$2.6M
$338.8M
Q3 24
$5.0M
$367.0M
Q2 24
$4.7M
$406.2M
Q1 24
$5.6M
$438.0M
Q3 23
$722.5K
Total Assets
LRHC
LRHC
ZYME
ZYME
Q3 25
$21.7M
$397.3M
Q2 25
$22.9M
$408.4M
Q1 25
$21.0M
$425.5M
Q4 24
$19.4M
$463.1M
Q3 24
$19.7M
$487.2M
Q2 24
$18.7M
$515.6M
Q1 24
$16.3M
$553.8M
Q3 23
$5.8M
Debt / Equity
LRHC
LRHC
ZYME
ZYME
Q3 25
0.41×
Q2 25
0.19×
Q1 25
Q4 24
0.25×
Q3 24
0.13×
Q2 24
0.14×
Q1 24
0.12×
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LRHC
LRHC
ZYME
ZYME
Operating Cash FlowLast quarter
$-1.3M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LRHC
LRHC
ZYME
ZYME
Q3 25
$-1.3M
$-31.4M
Q2 25
$-1.4M
$12.1M
Q1 25
$-3.5M
$-3.4M
Q4 24
$-1.1M
$-41.5M
Q3 24
$-591.6K
$-5.9M
Q2 24
$-803.1K
$-25.0M
Q1 24
$-538.3K
$-37.7M
Q3 23
Free Cash Flow
LRHC
LRHC
ZYME
ZYME
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
Q3 23
FCF Margin
LRHC
LRHC
ZYME
ZYME
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Q3 23
Capex Intensity
LRHC
LRHC
ZYME
ZYME
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Q3 23
Cash Conversion
LRHC
LRHC
ZYME
ZYME
Q3 25
Q2 25
-0.02×
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons